Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene in Heavy Drinkers: Role of OPRM1 Gene Variation
NCT02639273Phase 1Completed
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Start
- Jun 2016
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nalmefene in alcohol use disorder (AUD) (2 arms), sponsored by National Institute on Alcohol Abuse and Alcoholism. Primary endpoints: Nalmefene-induced BOLD signal changes in neural regions associated with alcohol reward processing, including ventral striatum, amygdala, and insula and Nalmefene-induced changes in IV alcohol self-administration. Started Jun 2016; status: completed.
02
Drugs
nalmefene
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT02639273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639273.